北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 肿瘤化疗科  > 期刊论文
学科主题: 临床医学
题名:
Comparison between late-course accelerated hyperfractionation radiotherapy and concurrent chemoradiotherapy in patients with esophageal carcinoma
作者: Lin, Qiang2; Gao, Xan-Shu1; Qiao, Xue-Yng3; Liu, Chao-Xng1; Zhou, Zhi-Guo3; Guo, Zhi-Jun2; Zhao, Yan-Nan2; Chen, Kun2; Asaumi, Juni-Chi4
关键词: esophageal neoplasm ; late-course accelerated hyperfractionation radiotherapy ; concurrent chemoradiotherapy
刊名: ONCOLOGY LETTERS
发表日期: 2011-05-01
DOI: 10.3892/ol.2011.287
卷: 2, 期:3, 页:557-564
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PHASE-I TRIAL ; COMBINED-MODALITY THERAPY ; RADIATION-THERAPY ; TOXICITY CRITERIA ; CANCER ; CISPLATIN ; PACLITAXEL ; 5-FLUOROURACIL ; CHEMOTHERAPY ; RTOG
英文摘要:

This study aimed to compare the efficacy of late-course accelerated hyperfractionation radiotherapy (LAFR) and concurrent chemoradiotherapy (CRT) in patients with esophageal carcinoma and to evaluate the side effects of the two treatments. A total of 22 patients with primary esophageal squamous cell carcinoma were prospectively treated with LAFR, while 25 patients, during the same period, served as the control group and received CRT. The 22 patients in the LAFR group received conventional fractionated radiotherapy of 30 Gy over a 3-week period (5 daily fractions of 2.0 Gy per week), followed by accelerated hyperfractionated radiotherapy of 30 Gy for 2 weeks (twice daily, 1.5 Gy per fraction, with a minimal interval of 6 h between fractions, 10 fractions per week). The 25 patients in the CRT group received conventional fractionated radiotherapy of 50 Gy for 5 weeks, with 5 daily fractions of 2.0 Gy per week. Chemotherapy was started on the first day of irradiation (cisplatin 52.5 mg/m(2) on Day 1 and 5-fluorouracil 700 mg/m(2) on Days 1-5, repeated four times every 28 days). The median survival time in the LAFR and CRT groups were noted to be 17 and 21 months, respectively. The 1- and 2-year overall survival rates were 63.6 and 31.6% in the LAFR group and 76 and 57.4% in the CRT group (chi(2)=1.670; P=0.196). The median local control in the LAFR group was 17 months, while that in the CRT group was not determined. The 1- and 2-year local control rates were 54.5 and 39% in the LAFR group while those in the CRT group were 82.2 and 66.1% (chi(2)=3.527; P=0.060). The overall survival and local control rates of the LAFR group were lower than those of the CRT group, although the difference was not significant. The metastasis rates of the two groups were also not significantly different (chi(2)=0.030; P=0.862). Both acute and late adverse events in the two groups were tolerated. The side effects, including hematological toxicities, severe nausea and vomiting, and severe anorexia were significantly less in the LAFR group than those in the CRT group (P<0.05). In this small-sample exploratory study, the overall survival and local control rates were lower with LAFR than with CRT, but the difference was not significant. Moreover, LAFR was found to have fewer side effects and be more cost-effective compared to CRT. The long-term effects on LAFR survival should be evaluated in a phase III clinical trial.

语种: 英语
WOS记录号: WOS:000290133200028
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/61284
Appears in Collections:北京大学第一临床医学院_肿瘤化疗科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Dept Radiat Oncol, Beijing 10034, Peoples R China
2.Gen Hosp, N China Petr Bur, Dept Oncol, Shijiazhuang 062552, Hebei, Peoples R China
3.Hebei Med Univ, Hosp 4, Dept Radiat Oncol 1, Shijiazhuang 050011, Hebei, Peoples R China
4.Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Field Tumor Biol, Dept Oral & Maxillofacial Radiol, Okayama 7008525, Japan

Recommended Citation:
Lin, Qiang,Gao, Xan-Shu,Qiao, Xue-Yng,et al. Comparison between late-course accelerated hyperfractionation radiotherapy and concurrent chemoradiotherapy in patients with esophageal carcinoma[J]. ONCOLOGY LETTERS,2011,2(3):557-564.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Lin, Qiang]'s Articles
[Gao, Xan-Shu]'s Articles
[Qiao, Xue-Yng]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Lin, Qiang]‘s Articles
[Gao, Xan-Shu]‘s Articles
[Qiao, Xue-Yng]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace